aTyr Pharma (NASDAQ:LIFE) Announces Earnings Results, Beats Expectations By $0.01 EPS

aTyr Pharma (NASDAQ:LIFE) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Yahoo Finance reports. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.11 million.

aTyr Pharma Stock Performance

LIFE traded up $0.01 during midday trading on Friday, reaching $1.61. The company had a trading volume of 258,118 shares, compared to its average volume of 498,541. The company has a quick ratio of 6.27, a current ratio of 6.27 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $1.77 and a two-hundred day moving average of $1.55. The company has a market cap of $109.38 million, a P/E ratio of -1.68 and a beta of 1.27. aTyr Pharma has a 1 year low of $1.08 and a 1 year high of $2.70.

Wall Street Analysts Forecast Growth

LIFE has been the subject of a number of analyst reports. Royal Bank of Canada reduced their price target on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 15th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $23.67.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.